Koki Kasamatsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Koki Kasamatsu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Nobuyuki Kanematsu
Department of Accelerator and Medical Physics, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, JAPAN
2 shared publications - Takamitsu Masuda
Department of Accelerator and Medical Physics, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, JAPAN
2 shared publications - Taku Inaniwa
Department of Accelerator and Medical Physics, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Chiba, 263-8555, JAPAN
2 shared publications - Yusuke Nomura
Department of Accelerator and Medical Physics, Institute for Quantum Medical Science National Institutes for Quantum Science and Technology Chiba Japan
2 shared publications - Hiroaki Ikawa
QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan
1 shared publication - Jiayao Sun
National Institutes for Quantum Science and Technology, 4-9-1, Anagawa, Inage-ku, Chiba, Chiba Prefecture, 263-8555, JAPAN
1 shared publication
Latest Publications
- 14 January 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (3)
Robustness of LET d -optimized multi-ion therapy against range and setup uncertainties: evaluation and enhancement with carbon-, oxygen-, and neon-ion beams
Objective: The LET trilemma—an inherent conflict between target dose homogeneity, range robustness, and high dose-averaged linear energy transfer (LET d )—poses a major challenge in treatment optimization. To ensure accurate beam delivery in multi-ion therapy, this study evaluated the effects of range and setup uncertainties on LET d -optimized treatment plans and explored strategies to overcome this trilemma, framed within the phase I LET d escalation trial for head and neck cancers. Approach: Six head and neck cancer patients representing diverse tumors were selected. Multi-ion therapy plans using carbon-, oxygen-, and neon-ion beams were optimized to achieve a target LET d of 90 keV/μm (the final LET d level of the phase I trial). These plans were recalculated to incorporate uncertainties arising from stopping power ratio conversion and random daily setup variations across the 16 fractions, and their combined effects on the dose and LET d distributions were evaluated. Additionally, to explore strategies to increase plan robustness, five modified plans were evaluated for one patient identified as particularly susceptible to these uncertainties. Main results: Range uncertainty was the dominant contributor to degraded plan quality in multi-ion therapy, substantially outweighing setup uncertainty. A small, centrally located tumor was most susceptible, exhibiting dose inhomogeneity of approximately 11%, while LET d variations were approximately 3 keV/μm. The most effective strategy involved replacing the original carbon−oxygen combination with oxygen ions for two beam ports, reducing dose inhomogeneity by more than 7% while maintaining normal tissue sparing adjacent to the target. Significance: Optimization toward achieving higher LET d makes treatment plans susceptible to range uncertainty, leading to dose degradation within small, deep-seated tumors. Employing heavier ions is an effective strategy to overcome this challenge, enabling robust target coverage by leveraging their inherently higher LET d while sparing normal tissues. These findings provide a key rationale for ion selection in the design of robust multi-ion therapy.
- 14 January 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (3)
Robustness of LET d -optimized multi-ion therapy against range and setup uncertainties: evaluation and enhancement with carbon-, oxygen-, and neon-ion beams
Objective: The LET trilemma—an inherent conflict between target dose homogeneity, range robustness, and high dose-averaged linear energy transfer (LET d )—poses a major challenge in treatment optimization. To ensure accurate beam delivery in multi-ion therapy, this study evaluated the effects of range and setup uncertainties on LET d -optimized treatment plans and explored strategies to overcome this trilemma, framed within the phase I LET d escalation trial for head and neck cancers. Approach: Six head and neck cancer patients representing diverse tumors were selected. Multi-ion therapy plans using carbon-, oxygen-, and neon-ion beams were optimized to achieve a target LET d of 90 keV/μm (the final LET d level of the phase I trial). These plans were recalculated to incorporate uncertainties arising from stopping power ratio conversion and random daily setup variations across the 16 fractions, and their combined effects on the dose and LET d distributions were evaluated. Additionally, to explore strategies to increase plan robustness, five modified plans were evaluated for one patient identified as particularly susceptible to these uncertainties. Main results: Range uncertainty was the dominant contributor to degraded plan quality in multi-ion therapy, substantially outweighing setup uncertainty. A small, centrally located tumor was most susceptible, exhibiting dose inhomogeneity of approximately 11%, while LET d variations were approximately 3 keV/μm. The most effective strategy involved replacing the original carbon−oxygen combination with oxygen ions for two beam ports, reducing dose inhomogeneity by more than 7% while maintaining normal tissue sparing adjacent to the target. Significance: Optimization toward achieving higher LET d makes treatment plans susceptible to range uncertainty, leading to dose degradation within small, deep-seated tumors. Employing heavier ions is an effective strategy to overcome this challenge, enabling robust target coverage by leveraging their inherently higher LET d while sparing normal tissues. These findings provide a key rationale for ion selection in the design of robust multi-ion therapy.
- 14 January 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (1) , 01TR03
Neon ion radiotherapy: physics and biology
Neon ion ( 20 Ne) beam radiotherapy was one of the primary particle therapy candidates investigated during the clinical trials beginning in the 1970s at the Lawrence Berkely National Laboratory (LBNL), which shut down in the early 1990s. Currently, therapeutic neon ion beams are available at only one clinical facility worldwide, the National Institutes for Quantum Science and Technology (QST) in Chiba, Japan. Recently, neon ion beams were commissioned at QST Hospital as part of the first clinical multi-ion therapy (MIT) program, which aims to improve clinical outcomes by escalating higher linear energy transfer (LET) radiation in the tumor for treating therapy-resistant disease. With the advancement of high-precision scanning delivery techniques, neon ion treatments in the present day could be delivered more safely and with greater precision compared to the first and only clinical application decades prior at LBNL using passive scattering technology. Despite their promising results, preclinical investigations of neon ions are scarce outside of Japan and further independent studies are needed. Clinically, neon ion therapy may offer benefits in treating certain malignancies by escalating LET in the tumor, but its limited availability and high costs restrict its current use and adoption. Studies have shown that 20 Ne or multi-ion mixtures ( 4 He, 12 C, 16 O and/or 20 Ne) can provide larger degrees of freedom in optimization of dose, LET and relative biological effectiveness, otherwise unattainable with other single ion techniques. Neon ion beams are under investigation in the ongoing MIT clinical trials which will establish their broader applicability. In this review, the technology, physics, radiobiology, and potential clinical applications of neon ion beams are outlined. The status of therapeutic neon ion beams is provided while discussing future research and clinical directions, including technological development of novel particle therapy delivery techniques, such as multi-ion, mini-beam, arc, and ultra-high dose rate.
- 14 January 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (1) , 01TR03
Neon ion radiotherapy: physics and biology
Neon ion ( 20 Ne) beam radiotherapy was one of the primary particle therapy candidates investigated during the clinical trials beginning in the 1970s at the Lawrence Berkely National Laboratory (LBNL), which shut down in the early 1990s. Currently, therapeutic neon ion beams are available at only one clinical facility worldwide, the National Institutes for Quantum Science and Technology (QST) in Chiba, Japan. Recently, neon ion beams were commissioned at QST Hospital as part of the first clinical multi-ion therapy (MIT) program, which aims to improve clinical outcomes by escalating higher linear energy transfer (LET) radiation in the tumor for treating therapy-resistant disease. With the advancement of high-precision scanning delivery techniques, neon ion treatments in the present day could be delivered more safely and with greater precision compared to the first and only clinical application decades prior at LBNL using passive scattering technology. Despite their promising results, preclinical investigations of neon ions are scarce outside of Japan and further independent studies are needed. Clinically, neon ion therapy may offer benefits in treating certain malignancies by escalating LET in the tumor, but its limited availability and high costs restrict its current use and adoption. Studies have shown that 20 Ne or multi-ion mixtures ( 4 He, 12 C, 16 O and/or 20 Ne) can provide larger degrees of freedom in optimization of dose, LET and relative biological effectiveness, otherwise unattainable with other single ion techniques. Neon ion beams are under investigation in the ongoing MIT clinical trials which will establish their broader applicability. In this review, the technology, physics, radiobiology, and potential clinical applications of neon ion beams are outlined. The status of therapeutic neon ion beams is provided while discussing future research and clinical directions, including technological development of novel particle therapy delivery techniques, such as multi-ion, mini-beam, arc, and ultra-high dose rate.